Mylan, Prosonix Use In Vitro Data To File Generic Fluticasone Inhaler In EU
This article was originally published in The Pink Sheet Daily
Marketing submissions for generic inhaled respiratory products based on in vitro data alone may be less expensive and a quicker route to market than other EU regulatory processes for inhaled generics.
You may also be interested in...
Prosonix receives an extra $9 million for its Series B round as it changes business strategy from contract research to the development of generic respiratory products, based on a novel particle-engineering technology for inhaled powders.
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.